游如旭，现任华中科技大学同济医学院附属协和医院药学部副主任，新加坡国立大学访问学者，武汉中青年医学骨干人才。同时担任中国研究型医院学会药物经济学专业委员会委员、中国医疗保健国际交流促进会药物经济学评价学组委员、湖北省药学会药物经济学专业委员会副主任委员、湖北省药品临床综合评价专家委员会委员、湖北省药学会药事管理专业委员会委员、武汉市青年药师专业委员会副主任委员等学术职务。
研究方向：药事管理，药物经济学
研究及获奖情况：近年来主持国家自然科学基金、国家卫健委、国家医保局等资助课题10余项，获湖北省科技进步一等奖1项（排名3/14）。以第一作者及通讯作者发表学术论文30余篇，其中SCI收录24篇，参编专著3部。
联系方式：ruxu.you@hust.edu.cn
主持课题：
1.国家自然科学基金（No.31500283）：石斛多糖调节肠道稳态防治肝纤维化的研究
2.国家卫生健康委医院管理研究所医院药学高质量发展研究项目（No.NIHAYS2324）：前列腺癌患者骨质疏松筛查策略及药物治疗的卫生经济学评价研究
3.国家卫生健康委医药卫生科技发展研究中心青年项目（No.WKZX2023CX200001）：男性骨质疏松筛查策略及药物治疗的卫生经济学评价研究
4.中国药学会优秀人才项目（No.XH20231205）：乳腺癌患者骨质疏松筛查策略及药物治疗的卫生经济学评价研究
5.湖北省自然科学基金项目（No.2015CFB533）：香菇多糖基于多靶点抗肿瘤分子机制的研究
6.湖北省卫生健康委员会（No.WJ2023F009）：骨质疏松治疗药物的临床综合评价
7.湖北省中医药管理局青年人才项目（No.2Y2023Q012）：中成药治疗骨质疏松症的药物经济学研究
8.湖北省药品（医疗器械）不良反应监测中心委托课题（No.XH20231023）：免疫检查点抑制剂在自身免疫性疾病患者抗肿瘤治疗中的安全性和有效性评价研究
9.吴阶平医学基金会临床科研专项（No.320.675.2024-6-39）：国家组织集中带量采购中标阿法骨化醇软胶囊疗效与安全性的真实世界研究
10.白求恩公益基金会面上项目：卡非佐米治疗成人复发或难治性多发性骨髓瘤的临床综合评价
11.北京药盾公益基金会：舒沃替尼与埃万妥单抗在EGFR外显子20插入突变非小细胞肺癌中的匹配调整间接比较
主要学术论文（第一或通讯作者）：
1. Hu Huiping (#), Fu Zhiwen, Liu Jinmei, Zhang Cong, Li Shijun, Zhang Yu,You Ruxu (*). Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database, Frontiers in Pharmacology, 2024,15:1339505.
2. Fu Zhiwen (#), Liu Jinmei (#), Zhang Cong, Hu Huiping, Li Shijun, Zhang Yu,You Ruxu (*). Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database, Frontiers in Pharmacology, 2024,15:1383212.
3. Chao Mei#, Baoli Xu (#), Xuefeng Cai, Min Wan, Zhigang Zhao, Yongning Lv, Yu Zhang,Ruxu You (*). Factors affecting the medication literacy of older adults and targeted initiatives for improvement: a cross-sectional study in central China, Frontiers in Public Health, 2024,11:1249022.
4. Yuansheng Wan (#), Jinyu Liu, Xiaolian Zhan, Yu Zhang,Ruxu You (*). Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China, Cost Effectiveness and Resource Allocation, Cost Effectiveness and Resource Allocation, 2023,21(1):93.
5. WY Wang (#), LH Chen, WJ Ma,RX You (*). Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials, European Review for Medical and Pharmacological Sciences, 2023,27 (17): 8253-8268.
6. Jinyu Liu (#), Dong Liu, Xuepeng Gong, Anhua Wei,Ruxu You (*). Cost-effectiveness of empagliflozin for the treatment of heart failure: a systematic review, Frontiers in Pharmacology, 2023,14:1186579.
7. Guangyi Yu (#), Suiju Tong (#), Jinyu Liu, Yuansheng Wan, Min Wan, Sujuan Li,Ruxu You (*). A systematic review of cost-effectiveness analyses of sequential treatment for osteoporosis, Osteoporosis International, 2022,34(4):641-658.
8. Y Wan (#), F Zeng, H Tan, Y Lu, Y. Zhang, L Zhao,R You (*). Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review, Osteoporosis International, 2022,33(5):979-1015.
9. Jinyu Liu (#), Min Guo, Lei Ke*,Ruxu You (*). Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review, Frontiers in public health, 2022,10:836986.
10.Ruxu You (#), Jinyu Liu, Lei Ke, Min Wan, Yu Zhang, Guangyi Yu (*), Takahiro Mori (*). Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China, Frontiers in Pharmacology, 2022,13:816248.
11.Ruxu You (#), Jinyu Liu (#), Lei Ke, Guangyi Yu, Yu Zhang, Takahiro Mori (*). Cost-Effectiveness of Sequential Teriparatide/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China, Frontiers in public health, 2022,10:794861.
12.Ruxu You (#), Takahiro Mori, Lei Ke, Yuansheng Wan, Yu Zhang, Fei Luo, Da Feng, Guangyi Yu, Jinyu Liu (*). Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China, Menopause - The Journal of The Menopause Society, 2021,29(2):210-218.
13.Jinyu Liu (#), Yu Zhang, Bin Wu, Sen Wang, David Bin-Chia Wu (*),Ruxu You (*). Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China, Frontiers in Pharmacology, 2021,12:717504.
14.Ruxu You (#), Zijie Liu (*). Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence, Frontiers in Pharmacology,2020,11:575893.
15.Ruxu You (#), Yu Zhang (#), David Bin-Chia Wu, Jinyu Liu, Xinyu Qian, Nan Luo and Takahiro Mori*. Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China, Frontiers in Pharmacology, 2020,11:456.
16.Ruxu You (#), Jinyu Liu, Zhihao Yang, Chenwei Pan, Qinghua Ma (*) and Nan Luo (*). Comparing the performance of the EQ-5D-3 L and the EQ-5D-5 L in an elderly Chinese population, Health and Quality of Life Outcomes, 2020.18(1):97.
17. Kaiping Wang (#), Xiawen Yang, Zhijing Wu, Hongjing Wang, Qiang Li, Hao Mei,Ruxu You (*), Yu Zhang (*). Dendrobium officinale Polysaccharide Protected CCl(4)-Induced Liver Fibrosis Through Intestinal Homeostasis and the LPS-TLR4-NF-κB Signaling Pathway, Frontiers in Pharmacology, 2020,11:240.
18.Ruxu You (#), Jinyu Liu (#), David Bin-Chia Wu, Xinyu Qian, Boxiang Lyu, Yu Zhang, Nan Luo (*). Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In, Cancer management and research, 2019,11:10239-10248.
19.Ruxu You (#), Xinyu Qian, Weijing Tang, Tian Xie, Fang Zeng, Jun Chen, Yu Zhang, and Jinyu Liu (*). Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review,Canadian respiratory journal, 2018,2018:1015239.
20. Kaiping Wang (#), Hanxiang Wana, Yage Lia, Weizhi Shui, Junfeng Wang, Peng Cao, Hongjing Wang,Ruxu You (*), Yu Zhang (*). Dendrobiurn officinale polysaccharide attenuates type 2 diabetes mellitus via the regulation of PI3K/Akt-mediated glycogen synthesis and glucose metabolism, Journal of Functional Foods, 2017,40:261-271.
21. Liu Jinyu (#), Liu Dong, Li Juan, Zhu Lan, Zhang Chengliang, Lei Kai, Xu Qiling,You Ruxu (*). Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials,2017,12(1):e0170246.
22. Jinyu Liu (#), Ming Song, Min Guo, Feng Huang, Bingjun Ma, Lan Zhu, Gang Xu, Juan Li,Ruxu You (*). Sirolimus Versus Tacrolimus as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation, American Journal of Therapeutics，2016,23(6):e1720-e1728.
23.Ruxu You (#), Jinyu Liu, Shijun Li, Liu Wang, Kaiping Wang (*), Yu Zhang (*). Alkali-soluble polysaccharide, isolated from Lentinus edodes, induces apoptosis and G2/M cell cycle arrest in H22 cells through microtubule depolymerization. Phytotherapy research,2014,28(12):1837-45.
24.Ruxu You (#), Kaiping Wang, Jinyu Liu, Maochang Liu, Li Luo, Yu Zhang (*). A comparison study between different molecular weight polysaccharides derived from Lentinus edodes and their antioxidant activities in vivo.Pharmaceutical biology.2011,49(12):1298-305.
25.游如旭（#），张聪,张玉.骨质疏松症治疗药物合理应用专家共识（2023）[J/OL].中国医院药学杂志,1-24[2024-03-05].
26.万元胜#,赵立波,刘金玉,曾芳,吕永宁,张玉,游如旭（*）.骨健康管理卫生经济学评价的趋势与热点：基于CiteSpace的可视化分析[J].中国医院药学杂志,2023,43(01):28-33.
27.吕鹏#,马芬芬,张玉,万元胜,黄怡菲,游如旭（*）.双膦酸盐用于儿童成骨不全治疗的快速卫生技术评估[J].中国医院药学杂志,2022,42(23):2500-2504.
28.万元胜#，赵立波，陈骏，吕永宁，张玉，游如旭（*）.唑来膦酸治疗骨质疏松症的快速卫生技术评估[J].中国药学杂志,2022,57(06):496-501.
29.陈骏#,赵立波,万元胜,汪柳,吕永宁,张玉,游如旭（*）.阿仑膦酸钠用于骨质疏松症治疗的快速卫生技术评估[J].中国医院药学杂志,2021,41(21):2227-2235.
30.游如旭（#），刘金玉,张玉,赵瑛,郑思维,黄璞*.应用Markov模型对厄贝沙坦和比索洛尔治疗高血压伴心衰的长期药物经济学评价[J].中国药学杂志,2017,52(24):2209-2213.
31.刘金玉#,王孝芳,游如旭（*）.1例卵巢癌伴脑转移患者的疼痛治疗方案调整与分析[J].中国药师,2017,20(11):2031-2033.
32.刘金玉#,刘东,张程亮,桂玲,吴红艳,游如旭（*）.基因多态性与羟考酮个体差异相关性的研究进展[J].中国疼痛医学杂志,2017,23(09):686-690.
33.游如旭（#），张玉,汪柳,张琪琳,王凯平*.香菇多糖诱导鼠肝癌H_(22)细胞凋亡机制的初步探讨[J].中国医院药学杂志,2015,35(09):776-781.
34.游如旭（#），王凯平,黄璞,周洪波,张玉*.香菇多糖注射液联合化疗治疗非小细胞肺癌的疗效与安全性的Meta分析[J].中国药房,2014,25(32):3033-3037.
